Chargement en cours...
Selpercatinib: First Approval
Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA f...
Enregistré dans:
| Publié dans: | Drugs |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer International Publishing
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7716849/ https://ncbi.nlm.nih.gov/pubmed/32557397 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01343-7 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|